Day One Biopharmaceuticals (DAWN) Stock Jumps 66% After Servier Acquisition Deal

TLDR

• Servier agreed to acquire Day One Biopharmaceuticals (DAWN) for $21.50 per share in an all-cash deal worth approximately $2.5 billion
• The offer represents a ~68% premium to DAWN’s closing price on Thursday and an 86% premium to its 30-day volume-weighted average price
• DAWN stock surged ~66% in premarket trading following the announcement on March 6, 2026
• Day One’s board unanimously approved the deal and recommended shareholders accept the tender offer
• The transaction is expected to close in Q2 2026, subject to antitrust clearance and majority tender conditions

---

Day One Biopharmaceuticals (DAWN) has agreed to be acquired by French pharma group Servier in an all-cash deal worth roughly $2.5 billion. The news sent DAWN stock up about 66% in premarket trading on Friday, March 6.

https://x.com/FenwickWest/status/2029944210065969265?s=20

Under the terms of the agreement, Servier will pay $21.50 per share for all outstanding Day One stock. That price is a 68% premium to DAWN’s closing price on Thursday and an 86% premium to its 30-day volume-weighted average price.

Day One Biopharmaceuticals, Inc., DAWN

The deal is not subject to a financing condition, which removes one common obstacle that can derail acquisitions. Closing is expected in Q2 2026, pending U.S. antitrust clearance and a majority tender from DAWN shareholders.

Day One’s board reviewed the terms and voted unanimously to recommend shareholders tender their stock. The company agreed to standard non-solicitation provisions and a break fee of $87.7 million if the deal falls apart under certain conditions.

The announcement didn’t come completely out of nowhere. DAWN stock had already moved higher on Wednesday following reports of takeover speculation, with Jazz Pharmaceuticals (JAZZ) and Ipsen (IPSEY) named at the time as possible suitors.

What Servier Gets

Servier’s main prize is Day One’s lead drug candidate, tovorafenib, which targets low-grade glioma — a type of brain tumor. The treatment has particular relevance in pediatric oncology, an area where Day One has focused most of its pipeline development.

For Servier, the deal extends its rare oncology franchise. The French group, which posted €6.9 billion in revenue for fiscal 2024/25, already invests close to 20% of its branded sales revenue back into R&D. Adding Day One’s assets fits its stated goal of becoming a stronger presence in targeted cancer therapies.

Deal Structure

The transaction is structured as an all-cash tender offer, followed by a second-step merger once conditions are met. The deal does not require Servier to secure new financing, which is seen as a sign of deal certainty.

The $87.7 million break fee provides some downside protection for Day One if the transaction doesn’t close as expected.

Prior to this deal, the most recent analyst price target on DAWN was $17.00 per share with a Buy rating — well below the $21.50 acquisition price.

DAWN’s market cap prior to the announcement stood at approximately $1.35 billion. The $2.5 billion deal value reflects the premium Servier is paying to secure the pipeline.

Day One is headquartered in Brisbane, California. The acquisition, if completed, will hand full ownership to Servier, an independent group based in France with medicines sold in more than 130 countries.

The post Day One Biopharmaceuticals (DAWN) Stock Jumps 66% After Servier Acquisition Deal appeared first on CoinCentral.